166 related articles for article (PubMed ID: 34493241)
21. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.
Brück O; Blom S; Dufva O; Turkki R; Chheda H; Ribeiro A; Kovanen P; Aittokallio T; Koskenvesa P; Kallioniemi O; Porkka K; Pellinen T; Mustjoki S
Leukemia; 2018 Jul; 32(7):1643-1656. PubMed ID: 29925907
[TBL] [Abstract][Full Text] [Related]
22. [Mechanism of cinnamic aldehyde-inducing apoptosis of chronic myeloid leukemic cells in vitro].
Liu LQ; Liu ZL; Wang X; Cui HY; Jin MD; Wang DY; Huang SA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):617-20. PubMed ID: 21729535
[TBL] [Abstract][Full Text] [Related]
23. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
24. MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML.
Liu YX; Wang L; Liu WJ; Zhang HT; Xue JH; Zhang ZW; Gao CJ
J Hematol Oncol; 2016 Aug; 9(1):69. PubMed ID: 27516205
[TBL] [Abstract][Full Text] [Related]
25. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
26. Retroviral vector-mediated transfer of the interferon-alpha gene in chronic myeloid leukemia cells.
Salesse S; Moreau-Gaudry F; Pigeonnier-Lagarde V; Mazurier F; Chahine H; Ged C; de Verneuil H; Reiffers J; Mahon FX
Cancer Gene Ther; 1998; 5(6):390-400. PubMed ID: 9917094
[TBL] [Abstract][Full Text] [Related]
27. [The immunological effect of anti-leukemic tumor induced by eosinophilic granulocyte].
Sun LF; Wu QQ; Hao HF; Ma XS; Du YH; Wang GC; Zhang JB
Zhonghua Nei Ke Za Zhi; 2013 May; 52(5):395-9. PubMed ID: 23945305
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
29. MiR-152-3p promotes the development of chronic myeloid leukemia by inhibiting p27.
Wang L; Wang Y; Lin J
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8789-8796. PubMed ID: 30575920
[TBL] [Abstract][Full Text] [Related]
30. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages.
Bhatia R; McGlave PB; Dewald GW; Blazar BR; Verfaillie CM
Blood; 1995 Jun; 85(12):3636-45. PubMed ID: 7780147
[TBL] [Abstract][Full Text] [Related]
31. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
[TBL] [Abstract][Full Text] [Related]
32. Generation of chronic myelogenous leukemia-specific T cells in cytokine-modified autologous mixed lymphocyte/tumor cell cultures.
Müller L; Provenzani C; Pawelec G
J Immunother; 2001; 24(6):482-92. PubMed ID: 11759071
[TBL] [Abstract][Full Text] [Related]
33. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
Dilloo D; Hanenberg H; Lion T; Burdach S
Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
[TBL] [Abstract][Full Text] [Related]
34. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
[TBL] [Abstract][Full Text] [Related]
35. Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib.
Hrdinova T; Toman O; Dresler J; Klimentova J; Salovska B; Pajer P; Bartos O; Polivkova V; Linhartova J; Machova Polakova K; Kabickova H; Brodska B; Krijt M; Zivny J; Vyoral D; Petrak J
Int J Oncol; 2021 Feb; 58(2):238-250. PubMed ID: 33491750
[TBL] [Abstract][Full Text] [Related]
36. [Regulation of wild type PTEN gene on Survivin, Xiap and Smac in chronic leukemia cells].
Cheng ZY; Wan JS; Wang YL; Liang LQ; Liang WT; Mu J; Lu X; Pan L
Zhonghua Yi Xue Za Zhi; 2011 Nov; 91(40):2868-72. PubMed ID: 22333553
[TBL] [Abstract][Full Text] [Related]
37. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
38. Effect of bone marrow mesenchymal stem cells from blastic phase chronic myelogenous leukemia on the growth and apoptosis of leukemia cells.
Han Y; Wang Y; Xu Z; Li J; Yang J; Li Y; Shang Y; Luo J
Oncol Rep; 2013 Aug; 30(2):1007-13. PubMed ID: 23733230
[TBL] [Abstract][Full Text] [Related]
39. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
[TBL] [Abstract][Full Text] [Related]
40. Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21.
Taverna S; Giallombardo M; Pucci M; Flugy A; Manno M; Raccosta S; Rolfo C; De Leo G; Alessandro R
Oncotarget; 2015 Sep; 6(26):21918-33. PubMed ID: 26116834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
